Biogen Inc.

Report azionario NasdaqGS:BIIB

Capitalizzazione di mercato: US$30.7b

Biogen Performance degli utili passati

Criteri Il passato verificati 0/6

Gli utili di Biogen sono diminuiti a un tasso medio annuo di -11%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 34.1%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 2.7%. Il ritorno sul capitale proprio di Biogen è 4.4% e ha margini netti di 8.3%.

Informazioni chiave

-11.05%

Tasso di crescita degli utili

-10.64%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.04%
Tasso di crescita dei ricavi-2.66%
Rendimento del capitale proprio4.43%
Margine netto8.32%
Ultimo aggiornamento sugli utili30 Jun 2026

Aggiornamenti sulle prestazioni recenti

Articolo di analisi • Feb 13

There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings

Shareholders appeared unconcerned with Biogen Inc.'s ( NASDAQ:BIIB ) lackluster earnings report last week. We think...

Recent updates

Seeking Alpha • Jul 29

Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade)

Summary Biogen Inc. is upgraded to 'Buy' as strategic acquisitions and pipeline progress offset multiple sclerosis portfolio erosion. Q2 revenue grew 3% Y/Y, aided by Apellis acquisition, rare disease, and Alzheimer's collaboration, with LEQEMBI gaining global traction. Felzartamab's multi-indication potential and upcoming pivotal trial readouts underpin BIIB’s long-term growth prospects. DCF analysis suggests BIIB is undervalued in the low-$200s, with valuation highly sensitive to growth acceleration above current 2-3% projections. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 22

BIIB: Tau Alzheimer’s Program And At-Home Alzheimer’s Regimen Will Drive Future Upside

Analysts have nudged their average price targets for Biogen higher, with the updated fair value estimate moving from about $219 to $228 as they factor in recent trial readouts, early Leqembi subQ approval, a slightly higher projected profit margin, a modestly lower assumed revenue growth rate, and a lower future P/E. Analyst Commentary Recent Street research on Biogen shows a mix of enthusiasm around the Alzheimer's pipeline and Leqembi franchise, paired with caution on execution risks, dose questions, and the pace of commercial uptake.
Aggiornamento narrativa • Jul 08

BIIB: Alzheimer’s Trial Uncertainty Will Likely Undermine Recent Acquisition Optimism

Biogen's analyst fair value estimate has been raised from $150.59 to $162.20 as analysts factor in higher price targets, a slightly lower discount rate, and more constructive views on the pipeline and the potential for a stabilizing core business. Analyst Commentary Recent Street research on Biogen shows a mix of optimism around the pipeline and caution around execution, valuation, and the balance of risks.
Aggiornamento narrativa • Jun 24

BIIB: Late Stage Neurology Readouts And Immunology Deals Will Drive Upside

Biogen's analyst price target edges higher, with a modest fair value move from about $279.24 to $279.94 as analysts factor in recent upgrades, revised models around the Apellis acquisition, and upcoming Alzheimer's data readouts such as diranersen at AAIC. Analyst Commentary Recent Street research on Biogen points to a cluster of constructive views around the Apellis acquisition, the Alzheimer’s franchise, and a broader late stage pipeline.
Aggiornamento narrativa • Jun 09

BIIB: Late Stage Neurology And Immunology Pipeline Will Drive Future Upside

Analysts have nudged their Biogen fair value estimate higher by about $6 to roughly $279, citing a combination of pipeline updates, a steadier core business and revised expectations for margins, growth and future P/E multiples as reflected in recent price target changes across the Street. Analyst Commentary Recent research points to a clear shift toward more constructive views on Biogen, with several bullish analysts lifting price targets and upgrading ratings as they reassess the pipeline and core franchises.
Aggiornamento narrativa • May 26

BIIB: Tau Alzheimer’s Data And EPS Upside Will Drive Future Upside

Biogen's updated analyst price target has shifted from about $206 to $219, as analysts weigh mixed but encouraging tau program data, potential EPS upside, and a modestly higher assumed future P/E multiple. Analyst Commentary Recent research views on Biogen cluster around mixed tau data, potential earnings power, and how much of that is already reflected in the stock's valuation.
Aggiornamento narrativa • May 04

BIIB: 2026 Readouts In Neurology And Immunology Will Drive Upside Potential

Analysts have lifted Biogen's fair value estimate by about $18 to $273.20 as they factor in updated revenue growth assumptions, a higher future P/E, and recent price target revisions across the Street. Analyst Commentary Recent Street research around Biogen has leaned constructive, with a cluster of fresh price target adjustments and several rating upgrades pointing to improving sentiment on execution and long term growth potential.
Aggiornamento narrativa • Apr 20

BIIB: 2026 Trial Outcomes Will Likely Undermine Recent Acquisition Optimism

Analysts made a slight upward adjustment to Biogen's fair value estimate to about $151, reflecting a blend of higher and lower price target revisions related to recent acquisition activity, pipeline updates, and shifting views on its long term earnings profile. Analyst Commentary Recent Street research around Biogen has been active, with a mix of higher and lower price targets clustered around the company’s acquisition activity, pipeline readouts, and changing expectations for longer term earnings power.
Aggiornamento narrativa • Apr 05

BIIB: 2026 Clinical Outcomes Will Likely Challenge Recent Neuroscience Optimism

The analyst price target for Biogen has been adjusted slightly to $150. This reflects recent model updates that incorporate a modestly higher discount rate, slightly lower revenue growth assumptions, a small uptick in expected profit margins, and Street research focusing on price target changes and evolving views on the company's pipeline and neurology portfolio.
Aggiornamento narrativa • Mar 22

BIIB: 2026 Clinical Readouts Will Likely Undermine Recent Pipeline Optimism

Analysts have nudged Biogen's fair value estimate higher to $151.48 from $147.47, reflecting a series of recent price target increases across the Street and ongoing reassessments of the company's pipeline and commercial outlook. Analyst Commentary Recent Street research around Biogen points to a mixed setup, with several firms adjusting price targets and ratings as they reassess the pipeline, commercial execution, and sector positioning.
Aggiornamento narrativa • Mar 07

BIIB: 2026 Clinical Readouts And Easing Policy Risks Will Drive Upside

The analyst fair value estimate for Biogen has increased by about $16 to $205.67 as analysts factor in recent price target revisions and updated views on the pipeline and commercial outlook. Analyst Commentary Recent research updates on Biogen cluster around revisions to price targets, refreshed models on the pipeline, and differing expectations for execution in 2026 and beyond.
Aggiornamento narrativa • Feb 21

BIIB: 2026 Clinical Readouts Will Likely Expose Pipeline Execution Risk

The analyst price target for Biogen has been raised from $143.00 to $147.47. Analysts point to a stronger profit margin outlook and updated pipeline and commercial assumptions as key drivers of the change.
Articolo di analisi • Feb 13

There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings

Shareholders appeared unconcerned with Biogen Inc.'s ( NASDAQ:BIIB ) lackluster earnings report last week. We think...
Aggiornamento narrativa • Feb 07

BIIB: 2026 Clinical Readouts And Pipeline Execution Will Drive Upside Potential

Analysts have nudged their price targets on Biogen higher, with our fair value estimate rising to about $255.45 from $247.88 as they update models for revenue growth, margins, and a modestly richer future P/E multiple following a series of mixed but generally upward target revisions across the Street. Analyst Commentary Recent research on Biogen has been mixed, but the pricing and modeling changes skew toward a constructive tone.
Aggiornamento narrativa • Jan 23

BIIB: 2026 Clinical Readouts Will Test Lofty Pipeline Expectations

Analysts have raised their Biogen fair value estimate from $128.00 to $143.00, citing refreshed models and higher Street price targets as they incorporate updated views on the pipeline, sector conditions, and 2026 catalysts. Analyst Commentary Street research around Biogen points to a generally more constructive view on the shares, with several firms lifting price targets into a range between about $180 and $225.
Aggiornamento narrativa • Jan 09

BIIB: Easing Policy Shifts And 2026 Pipeline Readouts Will Shape Outlook

Narrative Update: Biogen (BIIB) Biogen's fair value estimate has moved from about $181 to around $190 as analysts lift price targets into the $180 to $225 range and highlight updated models, slightly better margin and growth assumptions, and potential pipeline and sector catalysts through 2026. Analyst Commentary Recent research updates on Biogen cluster around a tighter valuation band in the high US$100s to low US$200s, with most firms revisiting their models and assumptions for 2025 to 2026.
Aggiornamento narrativa • Dec 24

BIIB: Easing Policy Overhangs And Alzheimer’s Data Will Shape Risk Reward Balance

Analysts have modestly raised their price target on Biogen, now implying upside in line with a slightly higher fair value of approximately $181, citing easing policy overhangs and a partial rerating of large-cap biopharma as investor focus shifts back to fundamentals. Analyst Commentary Street research on Biogen has turned incrementally more constructive, with several firms lifting price targets as macro and policy risks appear less threatening to the sector.
Aggiornamento narrativa • Dec 10

BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead

Analysts have modestly increased their price target for Biogen, lifting fair value by about $1 to roughly $179 per share. They cite easing policy overhangs, growing confidence in 2025 to 2026 fundamentals, and potential upside from Leqembi and the broader late stage pipeline.
Aggiornamento narrativa • Nov 26

BIIB: Policy Shifts And Drug Pipeline Progress Will Influence Risk And Reward Ahead

Biogen's analyst price target has been increased modestly, with the fair value estimate rising from $176.72 to $178.07. Analysts point to easing policy headwinds and renewed focus on company fundamentals amid recent sector re-ratings.
Aggiornamento narrativa • Nov 12

BIIB: Pipeline And Policy Developments Will Shape Risk And Reward Into 2025

Analysts have raised their price target for Biogen by approximately $4 to $176.72, citing improving sector fundamentals, easing policy risks, and a favorable risk/reward outlook as reasons for the adjustment. Analyst Commentary Recent street research on Biogen provides insight into both the optimistic and cautious perspectives that currently shape the stock's outlook.
Aggiornamento narrativa • Oct 29

Easing Policy Risks And New Therapy Launches Will Drive Shares Higher

Analysts have slightly raised their price target for Biogen to $172.55 from $172.34, reflecting modestly improved revenue growth expectations and an easing policy backdrop in the biotech sector. Analyst Commentary Recent street research reveals a spectrum of opinions around Biogen, highlighted by both bullish and bearish analyst actions.
Aggiornamento narrativa • Oct 15

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Analysts have slightly lifted their price targets for Biogen, with the updated fair value estimate rising from $170.03 to $172.34. This reflects improved profit margin expectations and easing industry headwinds cited in recent research updates.
Aggiornamento narrativa • Sep 20

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Biogen's modestly reduced consensus price target reflects a balanced analyst view, with optimism around strong Q2 performance, pipeline progress, and portfolio refocusing offset by lingering regulatory overhangs and a muted near-term growth outlook, resulting in a slight decrease in fair value from $171.96 to $170.03. Analyst Commentary Bullish analysts cite strong Q2 performance, particularly from Leqembi and the MS franchise, as well as solid sales across other programs as drivers for raised price targets.
Aggiornamento narrativa • Sep 05

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Biogen’s consensus price target was modestly raised as analysts highlighted strong Q2 performance, advancements in its neuro portfolio and pipeline, and ongoing portfolio refocusing, offsetting medium-term growth concerns and regulatory risks; the new fair value is now $171.96. Analyst Commentary Bullish analysts highlight strong Q2 performance, particularly in Leqembi and the MS franchise, combined with solid sales across other programs, supporting upward revisions in price targets.

Ripartizione dei ricavi e delle spese

Come Biogen guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storico di utili e ricavi

NasdaqGS:BIIB Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&S
30 Jun 2610,0288352,5951,871
31 Mar 269,9371,3722,4691,777
31 Dec 259,8911,2932,4341,729
30 Sep 2510,0661,6092,4301,771
30 Jun 259,9971,5312,4142,739
31 Mar 259,8161,4792,3811,902
31 Dec 249,6761,6322,3871,905
30 Sep 249,6081,6152,3141,967
30 Jun 249,6721,1592,4891,304
31 Mar 249,6631,1672,4762,326
31 Dec 239,8361,1612,5022,442
30 Sep 239,9931,4622,5322,490
30 Jun 239,9722,6652,3432,303
31 Mar 2310,1053,1312,3792,248
31 Dec 2210,1733,0472,4092,229
30 Sep 2210,3632,8652,5702,325
30 Jun 2210,6342,0592,6612,478
31 Mar 2210,8201,4502,7262,535
31 Dec 2110,9821,5562,6802,497
30 Sep 2111,1011,5462,7003,522
30 Jun 2111,6981,9182,6193,960
31 Mar 2112,6043,0122,5364,023
31 Dec 2013,4454,0012,5163,985
30 Sep 2014,2635,0822,3702,949
30 Jun 2014,4875,9272,3512,348
31 Mar 2014,4225,8792,3652,178
31 Dec 1914,3785,8892,3592,273
30 Sep 1914,2335,3962,2852,193
30 Jun 1914,0725,2942,2292,160
31 Mar 1913,8124,6672,1762,664
31 Dec 1813,4534,4312,1092,597
30 Sep 1813,2343,1872,0702,573
30 Jun 1812,8722,9682,0072,512
31 Mar 1812,5942,9641,9212,327
31 Dec 1712,2742,5391,9362,254
30 Sep 1711,8393,4861,8592,200
30 Jun 1711,7173,2931,8872,283
31 Mar 1711,5333,4801,9491,959
31 Dec 1611,4493,7031,9501,973
30 Sep 1611,4163,8852,0351,981
30 Jun 1611,2383,8182,0511,972
31 Mar 1610,9363,6952,0501,990
31 Dec 1510,7643,5472,1132,013
30 Sep 1510,5653,5992,1041,971

Guadagni di qualità: BIIB ha un grande una tantum perdita di $1.3B che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 30th June, 2026.

Margine di profitto in crescita: Gli attuali margini di profitto netti di BIIB (8.3%) sono inferiori rispetto allo scorso anno (15.3%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di BIIB sono diminuiti del 11% all'anno negli ultimi 5 anni.

Accelerare la crescita: BIIB ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.

Guadagni vs Settore: BIIB ha avuto una crescita negativa degli utili ( -45.5% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Biotechs ( 72.8% ).

Rendimento del capitale proprio

ROE elevato: Il Return on Equity ( 4.4% ) di BIIB è considerato basso.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/31 17:56
Prezzo dell'azione a fine giornata2026/07/31 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Biogen Inc. è coperta da 60 analisti. 29 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David ToungArgus Research Company
Brian SkorneyBaird
James BirchenoughBarclays